Insulin Glargine-aldy Injection, Solution
Product Images NDC 87682-080

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Insulin Glargine-aldy (NDC 87682-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lanexa Biologics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Insulin Glargine 1)

A line graph comparing the glucose infusion rates over time (hours after subcutaneous injection) between insulin glargine and NPH insulin. The x-axis shows time up to 30 hours, and the y-axis shows glucose infusion rate in mg/kg/min. The graph depicts a smoother, more prolonged glucose infusion rate for insulin glargine compared to a peak and decline for NPH insulin, with a marker indicating the end of the observation period.*

FDA Label Image

Figure2 (Insulin Glargine 2)

The image shows packaging of alcohol pads labeled "Alcohol Pad 75% Alcohol For Disinfection Use." These single-use swabs are typically used for skin disinfection before injections. The packaging is simple with blue text on white foil packets.*

FDA Label Image

Figure3 (Insulin Glargine 3)

An illustration of a medical sharps disposal container, shown as a white, wide-mouthed container with the word "SHARPS" clearly printed in bold, dark letters on its front. The container has a gray lid designed to securely close it.*

FDA Label Image

Figure4 (Insulin Glargine 4)

An anatomical illustration highlighting recommended subcutaneous injection sites for Insulin Glargine-aldy injection solution, including the upper arms, stomach, and thighs areas shaded in green on a human figure.*

FDA Label Image

Figure5 (Insulin Glargine 5)

An illustrated diagram showing components and parts of the Insulin Glargine-aldy injection pen. It includes the pen cap, pen needle with inner and outer needle caps and protective seal (needle not included), and the pen body with labeled insulin reservoir, rubber seal, insulin scale, plunger, dose window, dose selector, and injection button.*

FDA Label Image

Figure6 (Insulin Glargine 6)

Insulin Glargine-aldy 100 units/mL injection pen for subcutaneous use. The label prominently shows the product name and strength with dosage instructions for single patient use. The pen features a gray dial and a white body with blue and purple detailing. Manufactured by Lanexa Biologics, LLC.*

FDA Label Image

Figure7 (Insulin Glargine 7)

Packaging label of Insulin Glargine-aldy 100 IU/mL injectable solution. The label includes a QR code, places for lot number and expiration date, and features a blue and white color scheme on what appears to be a vial. The product is labeled for subcutaneous use and distributed by Lanexa Biologics, LLC.*

FDA Label Image

Figure8 (Insulin Glargine 8)

An instructional illustration showing how to remove the cap from an insulin glargine injection pen. The image depicts hands gripping the pen and pulling the cap off following the direction of a blue arrow pointing to the right.*

FDA Label Image

Figure9 (Insulin Glargine 9)

Insulin Glargine-aldy injection solution syringe for subcutaneous use, labeled for single patient use only. The syringe is marked with gradations for dosing, and the label specifies a strength of 100 units/mL (U-100). The product is manufactured by Lanexa Biologics, LLC.*

FDA Label Image

Figure10 (Insulin Glargine 10)

An instructional illustration showing a hand holding an insulin pen cartridge while wiping its rubber stopper with an alcohol swab, likely demonstrating preparation steps before injection for Insulin Glargine-aldy 100 IU/mL injection solution.*

FDA Label Image

Figure11 (Insulin Glargine 11)

An instructional illustration showing hands holding and preparing to twist an insulin pen needle cap, demonstrating the correct method to remove the cap before injection.*

FDA Label Image

Figure12 (Insulin Glargine 12)

An instructional illustration showing the removal of the cap from an insulin injection pen, labeled Insulin Glargine-aldy. Arrows indicate a twisting motion to remove the cap. A red circle with a cross shows not to pull the cap straight off.*

FDA Label Image

Figure13 (Insulin Glargine 13)

Illustration showing the preparation steps for Insulin Glargine-aldy 100 IU/mL injection solution. It depicts a hand holding the insulin pen injector and a separate image of a person cleaning the injection site with an alcohol swab before subcutaneous administration.*

FDA Label Image

Figure14 (Insulin Glargine 14)

An instructional illustration demonstrating the proper disposal of a used insulin pen needle into a container labeled 'SHARPS'. The image shows a hand placing the needle cap into the container, indicating safe handling and disposal of sharp medical waste.*

FDA Label Image

Figure15 (Insulin Glargine 15)

Illustration showing hands holding an insulin injection pen labeled Insulin Glargine-aldy 100 units/mL. The diagram focuses on the dose selector dial, highlighting how to turn the dial upward to set the desired dose before injection.*

FDA Label Image

Figure16 (Insulin Glargine 16)

An instructional illustration showing how to prepare an insulin pen for injection. The image highlights pressing the pen to expel a small spray of insulin from the needle tip, indicating flow check before administration.*

FDA Label Image

Figure17 (Insulin Glargine 17)

Insulin Glargine-aldy 100 units/mL injection in prefilled syringe form, designed for single use. The syringe features a clear barrel with measurement markings and a needle covered with a protective cap. The label includes the product name, strength, and dosage form, with Lanexa Biologics, LLC as the labeler.*

FDA Label Image

Figure18 (Insulin Glargine 18)

An instructional illustration showing a person holding an Insulin Glargine-aldy 100 units/mL injection pen. The image guides the user to remove the cap by lifting it upwards, with emphasis on the digital dose display and patient use label on the pen.*

FDA Label Image

Figure19 (Insulin Glargine 19)

An instructional diagram showing a close-up view of a dosing dial indicating that 20 units are selected. The image illustrates how to set the dose amount, likely for a subcutaneous insulin injection device.*

FDA Label Image

Figure20 (Insulin Glargine 20)

An instructional diagram showing a digital screen or device indicating '20' and '22' with a note stating '21 units selected,' likely representing a dosing selection or adjustment interface for insulin delivery.*

FDA Label Image

Figure21 (Insulin Glargine 21)

An instructional illustration showing a hand holding an insulin pen labeled Insulin Glargine-aldy 100 units/mL. The diagram includes an arrow pointing left, indicating the direction to inject the solution subcutaneously using the insulin injection pen.*

FDA Label Image

Figure22 (Insulin Glargine 22)

An instructional illustration showing a hand holding an Insulin Glargine-aldy injection pen, demonstrating how to remove the cap by pulling it straight off. The image includes close-up views emphasizing the correct and incorrect ways to remove the cap, with an arrow indicating the direction to pull and a red circle with a cross marking the incorrect method.*

FDA Label Image

Figure23 (Insulin Glargine 23)

An instructional illustration showing a hand holding an insulin pen injector with a thumb pressing the plunger. A timer icon indicates holding for 10 seconds, likely demonstrating the injection technique for insulin glargine-aldy subcutaneous injection.*

FDA Label Image

Figure24 (Insulin Glargine 24)

An instructional illustration showing removal of the cap from an injection pen device, likely representing the preparation step for subcutaneous injection of Insulin Glargine-aldy 100 units/mL solution. The image features two hands, one holding the pen and the other grasping the cap to pull it off, indicated by a blue arrow pointing right.*

FDA Label Image

Figure25 (Insulin Glargine 25)

An instructional illustration demonstrating the assembly or use of a prefilled pen-type injection device labeled Insulin Glargine-aldy. The diagram shows one hand holding the injection device and the other hand gripping a cap or needle cover, with arrows indicating a twisting motion and pressure points necessary for removing or attaching the cap.*

FDA Label Image

Figure26 (Insulin Glargine 26)

Illustration showing hands disposing of a used needle into a sharps container. One hand removes a cap from the needle, and the other hand is dropping the needle into a container labeled 'SHARPS.' The image demonstrates safe disposal of injection needles.*

FDA Label Image

Figure27 (Insulin Glargine 27)

An instructional illustration showing how to remove the outer cap from an insulin glargine-aldy prefilled pen injection device prior to use. The image demonstrates gripping the pen with one hand while pulling the cap off with the other hand along the indicated arrow direction.*

FDA Label Image

Carton (Insulin Glargine 28)

The image shows the packaging label for Insulin Glargine-aldy Injection 100 units/mL (U-100) from Lanexa Biologics, LLC. The label includes dosing warnings, storage instructions, and manufacturer information. The packaging states it is for subcutaneous use only and cautions against mixing with other insulins. The box design features blue and red text on a white background, includes a barcode, and provides space to record initial use dates for up to five pens.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.